Blood: In multiple myeloma, monoclonal immunoglobulin promotes bone loss

Most patients with multiple myeloma develop severe bone-soluble diseasesMyeloma cells secreteimmuneglobulin, the presence of monoclonal immunoglobulin in the serum of patients is importantdiagnosisstandardrecently, researchers have shown that adding immunoglobulins isolated from myeloma patients to in vitro-cultured bone-breaking prototherapy cells promotes bone-breaking cell differentiation, compared with immunoglobulins isolated in patients who never combine bone diseaseThis action is mainly mediated by immune complexes or aggregatesthis function and aggregation behavior of immunoglobulin depends in part on the glycogenic differences in the iglobulin Fc partGlycosylation analysis showed that patients with myeloma with ieloma with combined bone disease had significantly less semi-lactose on IgG and less salivary acid on IgG than in healthy peopleimportant, the researchers also observed a significant reduction in IgG saliva acidification in the serum of myeloma patients during bone diseaseIn the 5TGM1 mouse myeloma model, the researchers found that in mice treated with the salivary acid precursor N-acetyl glycoline (ManNAc), the number of bone damage decreased and the level of CTX-1, the active marker of bone-breaking cells, decreasedManNAc therapy increased saliva acidification in mice IgG-Fc, this study shows that in multiple myeloma, deglycosinated immunoglobulin promotes bone loss, alters IgG glycogenization, or can be used as a treatment strategy to reduce bone loss